Plaque Psoriasis Market

 Market Overview:

The 7 major plaque psoriasis markets reached a value of USD 12.7 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 32.3 Billion by 2035, exhibiting a growth rate (CAGR) of 8.89% during 2025-2035.

The plaque psoriasis market has been comprehensively analyzed in IMARC's new report titled "Plaque Psoriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Plaque psoriasis is a chronic autoimmune disease characterized by the formation of raised, red, scaly skin patches known as plaques. These plaques can vary in size and location but are typically found on the elbows, knees, scalp, and lower back. They can be itchy, painful, uncomfortable, and even bleed in severe cases. Various other symptoms may include dry and cracked skin, joint pain or stiffness, nail changes like pitting or separation from the nail bed, etc. In addition to the physical indications, the ailment can significantly impact a person's mental health and quality of life, causing embarrassment, social isolation, and depression. The diagnosis of plaque psoriasis involves a physical examination of the affected skin, including an assessment of the size, shape, and location of the plaques. A doctor may also ask about family history, medical history, and any other symptoms the patient may be experiencing. In some cases, a skin biopsy is necessary to confirm the diagnosis. Numerous other procedures, such as blood tests, joint X-rays, or a skin scraping to check for fungal infection, may be recommended if there are concerns about related conditions or further possible causes of symptoms.

The increasing cases of immune system dysfunction in which the immune system mistakenly attacks healthy skin cells, leading to inflammation and the formation of plaques, are primarily driving the plaque psoriasis market. Moreover, the escalating utilization of Vitamin D analogs, such as calcipotriene and calcitriol, for reducing the severity of disease symptoms, including scaling, redness, itching, etc., and decreasing the thickness of plaques is further augmenting the market growth. Besides this, the widespread adoption of phototherapy as a treatment option since it is well-tolerated, helps to prevent flare-ups, and improves skin texture is also creating a positive outlook for the market. Furthermore, various key players are making extensive investments in developing novel therapies to manage cytokines and other immune system proteins that promote skin inflammation and the formation of psoriatic plaques. This, in turn, is acting as another significant growth-inducing factor. Additionally, the inflating demand for biologics, which target specific proteins in the immune system to reduce inflammation, for treating moderate to severe psoriasis that has not responded to other treatments, is expected to drive the plaque psoriasis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the plaque psoriasis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for plaque psoriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the plaque psoriasis market in any manner.

Recent Developments:

• In August 2024, Alumis Inc. started patient dosing in the ONWARD Phase 3 clinical trial. This program includes two identical 24-week global Phase 3 clinical trials (ONWARD1 and ONWARD2) to evaluate ESK-001's efficacy and safety in adults with moderate-to-severe plaque psoriasis, as well as a long-term extension (LTE) trial, ONWARD3, to assess response durability and long-term safety.
• In October 2023, UCB reported that BIMZELX (bimekizumab-bkzx) had been approved by the United States Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in people who are candidates for systemic medication or phototherapy. Bimekizumab's approval is based on results from three Phase 3, multicenter, randomized, placebo and/or active comparator-controlled trials (BE READY, BE VIVID, and BE SURE), which assessed the effectiveness and safety of bimekizumab in 1,480 individuals with moderate to severe plaque psoriasis.
• In July 2023, the Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis. The trial met all of its primary and secondary efficacy goals. At week 16, a higher number of patients who received JNJ-2113 achieved PASI 75 (primary endpoint), PASI 90, and PASI 100 (75, 90, and 100 percent improvement in skin lesions as measured by the Psoriasis Area and Severity Index, respectively) a than placebo.

Key Highlights:

• In the United States, plaque psoriasis affects 1-2% of the population.
• When both parents have psoriasis, the incidence among probands' siblings might reach 50%. When one parent is affected, the incidence is 16.4%. When neither parent has psoriasis, only 7.8% of probands' siblings are affected.
• Plaque psoriasis is more common in girls than males among children and adolescents.
• Plaque psoriasis develops throughout two peak age ranges. The first peak occurs in those aged 16 to 22, while the second occurs in people aged 57 to 60 years.
• Females acquire plaque psoriasis earlier than males, and patients with a favorable family history of psoriasis are likely to have an earlier onset.

Drugs:

Izokibep is a novel bispecific agent that targets both subunits of IL-17A and albumin, both of which are prevalent in psoriatic skin. It was designed to utilize the strengths of Affibody's technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life.

Enbrel (Etanercept) is recommended for the treatment of moderate to severe plaque psoriasis in adults and children aged 4 and above. It's supposed to connect to TNF proteins to limit their function and assist in reducing joint pain, stiffness, and skin lesions of psoriatic arthritis.

JNJ-2113 is the first targeted oral peptide designed to block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque PsO and other IL-23-mediated diseases. JNJ-2113 binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the plaque psoriasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the plaque psoriasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current plaque psoriasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the plaque psoriasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the plaque psoriasis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the plaque psoriasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of plaque psoriasis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of plaque psoriasis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of plaque psoriasis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with plaque psoriasis across the seven major markets?
• What is the size of the plaque psoriasis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of plaque psoriasis?
• What will be the growth rate of patients across the seven major markets?
   

Plaque Psoriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for plaque psoriasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the plaque psoriasis market?
• What are the key regulatory events related to the plaque psoriasis market?
• What is the structure of clinical trial landscape by status related to the plaque psoriasis market?
• What is the structure of clinical trial landscape by phase related to the plaque psoriasis market?
• What is the structure of clinical trial landscape by route of administration related to the plaque psoriasis market?